Associate Professor of Nephrology @inselgruppe and @unibern. Kidney stone and rare kidney disease enthusiast. Passion for skiing, climbing and alpinism.
Switzerland
Joined March 2023
- Tweets141
- Following109
- Followers79
- Likes121
The next edition will take place in Switzerland in 2030. Stay tuned for updates as plans for this landmark gathering take shape.
This premier quadrennial meeting, first held in 1968, has a long and distinguished history. The outstanding 2026 edition was organized and led by David Goldfarb and Glenn Preminger, continuing a tradition that has spanned nearly six decades.
Daniel G. Fuster retweeted
My (devil's advocate) perspective:
Henderson-Hasselbach & Stewart are equivalently accurate for clinical diagnosis & management of acid-base abnormalities.
Stewart is fine, but it causes people to speak a different language that leads to confusion (most clinicians use H-H).
People mess up acid-base because they aren't paying attention (e.g., ignoring an elevated anion gap or a low bicarb). I'm always surprised by how a potassium of 3.4 mM causes alarm, but a bicarb of 14 mM is often ignored.
Transitioning from H-H to Stewart will make you seem fancy and smart, but it won't improve your clinical acumen. If anything, it will slow you down.
The best approach to clinical acid-base is a simple model that is widely utilized (H-H) and easy to apply broadly and uniformly (e.g., this approach emcrit.org/ibcc/agma/).
Part 2 of the acid–base series will be out tomorrow on thedependentvariable.com
This one is entirely about the chemistry behind Stewart: strong ions, weak acids, SID, electroneutrality, where the H⁺ comes from, and what “independent” and “dependent” variables actually mean.
I wanted to take the time to explain the bits that are usually skipped over.
Part 3 will then bring it all back to the bedside.
Daniel G. Fuster retweeted
Our new study is just published! We identified an association in >300 people, then followed up in mice and cells. Our findings point to a new potential hormonal cascade whereby high salt intake increases cortisol, which may suppress FGF23.
Link: doi.org/10.1007/s00424-026-0…
Daniel G. Fuster retweeted
New mechanistic piece of the SGLT2 puzzle: direct activation of PANK1 in the human heart → ↑CoA → improved cardiac energetics and function.
The kidney–heart understanding just became even more interesting.
Science science.org/doi/10.1126/scie…
How do you spacially restrict membrane transporter activity ? Use lipids ! nature.com/articles/s41467-0…
New hope for people with kidney stones: The EMPASTONE trial launched yesterday with enrollment of the first 2 patients.
More:
empastone.ch
clinicaltrials.gov/study/NCT…
Daniel G. Fuster retweeted
Klotho, the "longevity protein," has long been a black box — we knew kidneys produced it, but not how it worked. #CityUHK Professor Ganesh Pathare, in collaboration with Professor Johannes Loffing, from the University of Zurich, have finally mapped its precise kidney functions - cracking the code! 🔑
Two game-changing discoveries:
🌟 Distal tubule Klotho → regulates calcium & bone health
🌟 Proximal tubule Klotho → maintains phosphate & circulating sKlotho levels
Overturning long-held assumptions, this study opens new doors for treating chronic kidney disease! 🩺
🔗 Read more: go.cityu.hk/tlivyt
Daniel G. Fuster retweeted
A couple of highlights of the 63th ERA Congress held in Glasgow last week are presented in the M@H recording which will be streamed tomorrow evening (7:30 pm CET) - in-depth and more detailed discussions of the presented trials.
youtube.com/watch?v=OxbYH9yO…
Daniel G. Fuster retweeted
It was a huge pleasure to work alongside a global team and contribute to the CKD series published in @TheLancet (article 1 out of 3).
thelancet.com/series-do/chro…
Prevention of urinary stones with hydration: a randomised clinical trial of an adherence intervention - The Lancet thelancet.com/journals/lance…
Congratulations to the study team for the conduct of this trial. Longterm adherence to dietary recommendations remains a major challenge…..
Daniel G. Fuster retweeted
Obinutuzumab shows significant efficacy in active SLE.
Original Article: Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus (phase 3 ALLEGORY trial) nejm.org/doi/full/10.1056/NE…
#SLEuro | @SLEuroSociety
ALT Panel A: Time to first British Isles Lupus Assessment Group (BILAG)–defined flare. The time to event in weeks was calculated as the event date minus the randomization date plus 1, divided by 7. Panel B: Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores in the two trial groups at all assessed time points; only observed values are shown, and the I bars indicate Wald 95% confidence intervals.
ALT Panels A and B: The percentage of patients with normal C3 complement levels (≥0.9 g per liter) and normal C4 complement levels (≥0.1 g per liter), respectively, per visit, from baseline through week 52, among patients with abnormal baseline levels (for C3 levels, 87 patients in the obinutuzumab group and 85 patients in the placebo group; for C4 levels, 67 patients in the obinutuzumab group and 80 patients in the placebo group). Panel C: The percentage of patients with normal anti–double-stranded DNA antibody levels (<100 IU per milliliter) per visit, from baseline through week 52, among patients with abnormal baseline levels (86 patients in the obinutuzumab group and 81 patients in the placebo group). Panel D: The percentage of patients with B-cell depletion per visit, from baseline through week 52, in the obinutuzumab and placebo groups.
Daniel G. Fuster retweeted
Join this global initiative, CRESCENDO, which collects data on patients with crescentic lesions on their kidney biopsy. Reach out to one of the team members. 6 continents, over 100 centers have registered already!
academic.oup.com/ckj/advance…
@AnnetteBruchfe1 and Vanja Ivkovic
Daniel G. Fuster retweeted
🚀 STOP-PKD-News!
Das zweite Prüfzentrum in Mainz ist nun offiziell freigegeben. Weitere folgen (DE, NL, ES, AT).
Kann SGLT2-Inhibition das Fortschreiten von Zystennieren positiv beeinflussen?
Infos und Kontakte: stop-pkd.de/
#STOPPKD #ADPKD
@PKD_Int
Daniel G. Fuster retweeted
I am glad to work together with leading experts in the field of rare kidney diseases! Together these diseases are common! Thank you @GlomCon
🚨 We are pleased to announce the upcoming launch of GlomCon’s Rare Kidney Disease Journal, a new peer-reviewed journal developed in partnership with @SpringerNature. This journal will serve as a global platform dedicated to advancing research, clinical practice, and innovation in rare and complex kidney diseases.
Daniel G. Fuster retweeted
🧩 Many have wondered why the 1st-gen anti-miR-17 oligo RGLS4326 for #ADPKD didn’t advance, despite promising early clinical data.
💉At very high doses, it caused CNS toxicity in preclinical studies.
Our @NatureComms paper explains why
🔗 nature.com/articles/s41467-0…
Daniel G. Fuster retweeted
IgA Nephropathy with two global leaders @MarkusAtHome:
An honor and pleasure to host
@IgAN_JBarratt @jradnephro
For our best of @NDTsocial webinar picked by @AKronbichler @hjanders_hans
youtu.be/l0g9_lkW5_w?si=cuVq… via @YouTube
